Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Novabridge Biosciences ADR (NBP)

Novabridge Biosciences ADR (NBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer GlobeNewswire - Mon Jun 29, 6:00AM CDT

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines...

IVVD : 0.7841 (-0.48%)
NBP : 1.7900 (-0.28%)
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer GlobeNewswire - Tue Jun 16, 6:00AM CDT

Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE)...

NBP : 1.7900 (-0.28%)
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference GlobeNewswire - Thu May 28, 6:00AM CDT

ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.7900 (-0.28%)
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference GlobeNewswire - Tue May 12, 6:00AM CDT

ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.7900 (-0.28%)
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value GlobeNewswire - Wed Apr 22, 6:00AM CDT

Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commercial...

NBP : 1.7900 (-0.28%)
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Tue Apr 7, 3:50PM CDT

Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept data Givastomig, a potential...

NBP : 1.7900 (-0.28%)
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer GlobeNewswire - Mon Mar 16, 6:00AM CDT

FDA confirmed givastomig’s potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response...

NBP : 1.7900 (-0.28%)
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study GlobeNewswire - Mon Mar 9, 6:00AM CDT

VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment...

NBP : 1.7900 (-0.28%)
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 GlobeNewswire - Tue Mar 3, 8:05AM CST

VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD,...

NBP : 1.7900 (-0.28%)
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference GlobeNewswire - Mon Mar 2, 6:00AM CST

ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...

NBP : 1.7900 (-0.28%)

Barchart Exclusives

Despite AI Disappointments, Alphabet (GOOG) Stock Options Could Be Favorably Mispriced Barchart - 5 minutes ago
Although the smart money is paying more premiums for downside protection, there’s a quantitative case for bullishly betting on GOOG stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.